NMN vs NR: Which NAD+ Precursor Is Better for Longevity?

NAD+ (nicotinamide adenine dinucleotide) is one of the most intensively studied molecules in longevity science. As a cofactor for sirtuins, PARP enzymes, and the electron transport chain, NAD+ sits at the intersection of DNA repair, energy metabolism, circadian rhythm regulation, and cellular stress response. Its decline with age — roughly 50% between ages 40 and 60 in human tissues — has driven enormous interest in supplements that can restore youthful NAD+ levels.

Two molecules have emerged as the leading NAD+ precursors with human clinical trial data: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). They share a metabolic relationship: both are converted into NAD+ in cells, and NR is converted into NMN as part of its metabolic pathway. Despite this overlap, they have distinct pharmacokinetics, tissue distribution patterns, clinical trial profiles, and price points.

**NMN — Nicotinamide Mononucleotide**

NMN is structurally one metabolic step closer to NAD+ than NR. Research published in Nature Metabolism identified a specific NMN transporter (Slc12a8) in mouse intestinal cells, and subsequent human pharmacokinetic studies confirmed that oral NMN raises blood NMN levels within 2–3 hours of ingestion. A landmark 2022 human trial (Yoshino et al., Washington University) found that NMN supplementation at 250mg/day for 10 weeks increased skeletal muscle NAD+ levels and improved insulin sensitivity in postmenopausal women with prediabetes.

The David Sinclair lab at Harvard has published extensively on NMN in mouse models, showing improvements in muscle function, energy, and lifespan. NMN dosing in human trials has ranged from 100mg to 1,200mg daily, with 250–500mg being the most common range. NMN is generally more expensive than NR, typically $1–3 per day for 300–500mg.

**NR — Nicotinamide Riboside**

NR has a strong human clinical trial database, largely because it has been commercially available longer and has attracted substantial institutional research funding. Key NR findings: a 2018 Cell Metabolism study (Martens et al., University of Colorado) showed NR at 500mg/day for 6 weeks increased whole-blood NAD+ by 60% and reduced aortic stiffness and systolic blood pressure in healthy middle-aged and older adults. A 2023 trial in long COVID patients showed NR reduced fatigue and cognitive symptoms with improvement in mitochondrial function markers. NR appears to be preferentially taken up by certain tissues, particularly the liver.

**Head-to-head comparison**

No large human trial has directly compared NMN and NR in a randomized, controlled head-to-head design. The available evidence suggests both effectively raise blood and tissue NAD+ levels, but with potentially different tissue distribution. Animal data hints that NMN may be more effective in muscle tissue while NR may be preferentially hepatic, but this requires human confirmation.

From a practical standpoint: both are safe, both raise NAD+, and the clinical effect sizes observed to date are modest but meaningful. Price and personal response may be the most practical differentiators.

**Combining with other NAD+ modulators**

Some practitioners recommend combining NMN or NR with TMG (trimethylglycine) to support the methylation cycle, as NAD+ precursor metabolism can consume methyl groups. Apigenin, which inhibits CD38 (a major NAD+-consuming enzyme), has generated interest as a NAD+-boosting complement. Resveratrol activates SIRT1, one of the primary NAD+-dependent sirtuins, and may potentiate NAD+ precursor effects.

**The bottom line**

The NMN vs NR question does not yet have a definitive evidence-based winner. Both are reasonable choices for adults over 40 seeking to support NAD+ levels. NR has a slightly larger human trial database; NMN has more mechanistic excitement and a stronger identity in the longevity community. Choosing based on price, supplier quality, and personal response is rational given the current state of evidence.